By John Umeh
Nigeria has taken a major step in its fight against HIV with the arrival of Lenacapavir, a long-acting preventive injection designed to protect people at risk of infection. Health authorities say the new medication represents a significant advancement in the country’s efforts to curb the spread of the virus.
The breakthrough drug was approved for use by the Coordinating Minister of Health and Social Welfare, Muhammad Ali Pate, with support from the Global Fund to strengthen Nigeria’s national HIV response.
A New Option for HIV Prevention
Lenacapavir is used for pre-exposure prophylaxis (PrEP), a preventive strategy for people who are HIV-negative but at higher risk of infection. Unlike traditional PrEP medications that must be taken daily in pill form, the injection is administered just twice a year, offering a far more convenient alternative.
Public health specialists believe the longer-acting approach could improve adherence, particularly among individuals who struggle to maintain a daily medication routine.
Strengthening Nigeria’s HIV Response
According to Adebobola Bashorun, National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme (NASCP), the introduction of Lenacapavir reflects Nigeria’s determination to adopt innovative, evidence-based solutions in the battle against HIV.
He noted that expanding access to modern prevention tools while improving healthcare delivery systems will play a crucial role in reducing new infections and improving treatment outcomes nationwide.
Plans for National Rollout
Health authorities say NASCP will work closely with partners and stakeholders to ensure the safe distribution and effective integration of Lenacapavir into Nigeria’s HIV prevention programmes.
The drug is expected to be made available not only in Nigeria but also across 119 low- and middle-income countries. Through voluntary licensing agreements with generic drug manufacturers, the estimated annual cost is projected to be about $40 per person, making the medication more accessible in resource-limited settings.
Toward Ending HIV as a Public Health Threat
Health officials believe the introduction of long-acting prevention options like Lenacapavir could significantly accelerate progress toward ending HIV as a major public health challenge.
With improved prevention tools, expanded awareness, and stronger healthcare systems, Nigeria hopes to reduce new infections and move closer to achieving global targets for controlling the epidemic.
